SCM-198 Can Regulate Autophagy Through the Bax/Bcl-2/TLR4 Pathway to Alleviate Renal Ischemia-Reperfusion Injury

• Published in: The eurobiotech journal Vol. 5; no. 4; pp. 161 - 169
• Main Authors: Eraslan, Ersen, Bircan, Burak, Tanyeli, Ayhan, Can Güler, Mustafa, Bayır, Yasin, Altun, Serdar
• Format: Journal Article
• Language: English
• Published: Sciendo 21.10.2021
• Subjects: Autophagy; Bax; Bcl-2; Inflammatory cytokines; Renal injury; Renal ischemia-reperfusion; SCM-198
• ISSN: 2564-615X; 2564-615X
• DOI: 10.2478/ebtj-2021-0025

Renal ischemia-reperfusion (I/R) injury is frequently observed in several clinical cases. In this study, we want to investigate that SCM-198 attenuates renal injury in the renal I/R model and find out the possible mechanisms. Wistar albino 40 male rats were classified into four groups (n=10): control, DMSO, I/R, and SCM-198 30 mg/kg. In the group 4, SCM-198 was administered intraperitoneally once at the doses of 30 mg/kg following the reperfusion. Glomerular associated proteins (PCX), tubular damage factors (NGAL, KIM-1), blood urea nitrogen (BUN), serum creatinine, inflammatory cytokines (IL-1β, IL-18, and TNF-α), Bax/Bcl-2, TLR4, LC3B, and Beclin-1 were evaluated. SCM-198 played an essential role in mitigating kidney damage. SCM-198 alleviated tubular damage and decreased IL-1β, IL-18, and TNF-α levels. SCM-198 reduced the apoptosis marker Bax/Bcl-2 ratio, immune system protein TLR4, and autophagy proteins LC3B and Beclin-1. In brief, our results support the notion that SCM-198 has protective effects on I/R-induced renal injury. SCM-198 therapy may be a new alternative for the prevention and treatment of renal I/R injury.